PCR London Valves Issue

NEW ISSUE

Nov 18
PCR London Valves Issue

2024 Core Curriculum on Percutaneous Valvular and Structural Heart Disease Interventions; a mini focus on redo- TAVI; outcomes of low-flow, low-gradient aortic stenosis after TAVI; worsening LVEF after M-TEER; the MitraCut procedure; referral trends in T-TEER; debating PCI for bystander CAD; news from the EAPCI; and more


Trial Design

Nov 14
Rationale and design of the TAILORED-CHIP trial
Hanbit Park, Duk-Woo Park, et al.
The TAILORED-CHIP trial evaluates a time-dependent tailored antiplatelet therapy strategy of early escalation and late de-escalation versus standard DAPT in patients undergoing complex high-risk PCI.
Rationale and design of the TAILORED-CHIP trial

ORIGINAL RESEARCH

Nov 7
A novel SCB for de novo coronary lesions
Bruno Scheller, et al.
This non-inferiority trial compared a novel sirolimus-coated balloon to a paclitaxel-coated balloon in the treatment of de novo coronary lesions, demonstrating similar angiographic outcomes at 6 months.
A novel SCB for de novo coronary lesions

Original Research

Nov 12
Natural history of a newly developed calcified nodule
Yoichiro Sugizaki, Akiko Maehara, et al.
This study found that new calcified nodules developed in 7.0% of untreated calcified lesions, and were associated with larger calcium volume, greater hinge motion, and longer follow-up, resulting in worse clinical outcomes.
Natural history of a newly developed calcified nodule

EDITORIAL

Nov 7
SCB use in PCI
Robert W. Yeh, Christina Lalani
The study discusses the use of paclitaxel drug-coated balloons for treating coronary in-stent restenosis and the potential advantages of sirolimus-coated balloons over paclitaxel-coated balloons.
free

NEW ISSUE

Nov 4
A novel sirolimus-coated balloon; the natural history of newly developing calcified nodules;

ultrathin-strut vs thin-strut DES vs DEB in treating DES restenosis; TAILORED-CHIP trial design examining time-based antiplatelet therapy in high-risk PCIs; and more

A novel sirolimus-coated balloon; the natural history of newly developing calcified nodules;

ORIGINAL RESEARCH

Nov 4
Ultrathin DES for in-stent restenosis
Ovidio De Filippo, Wojciech Wańha, et al.
This study compared the efficacy of ultrathin-strut drug-eluting stents, thin-strut drug-eluting stents, and drug-eluting balloons for the treatment of drug-eluting stent in-stent restenosis. Ultrathin-strut drug-eluting stents were associated with reduced risk of device-oriented composite endpoints, target lesion revascularization, and target vessel revascularization in patients with diffuse in-stent restenosis.
Ultrathin DES for in-stent restenosis
Meet Cory, your AI Assistant!
Enhance your reading experience and get deeper insights on complex topics.
Learn more


TAVI patients with bystander coronary artery disease should receive PCI: pros and cons

DEBATE

Nov 18
TAVI patients with bystander coronary artery disease should receive PCI: pros and cons

The management of concomitant coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) remains a debated issue, weighing the potential prognostic benefits of treating CAD against the procedural risks and uncertain outcomes.

free

Receive our newsletter
Subscribe banner

Ahead of print

Oct 27
FFR-CT in patients with high-risk NSTE-ACS
David Meier, Stephane Fournier et al.

In patients with high-risk non-ST-elevation acute coronary syndrome, FFR-CT has superior diagnostic performance compared to CCTA alone in ruling out significant coronary artery disease and reducing unnecessary invasive procedures.

FFR-CT in patients with high-risk NSTE-ACS
free

Viewpoint

Oct 31
The invisible gorilla in the cath lab
João Silva-Marques and Catarina Oliveira
The article discusses the potential for cognitive illusions and perceptual errors in the cardiac catheterization laboratory and proposes an integrated approach to address these issues, drawing parallels with the aviation industry.
free

Original Research

Oct 31
ISCHEMIA 3-vessel disease
Sripal Bangalore, Judith S. Hochman, et al.
In patients with 3-vessel coronary artery disease, revascularization with PCI or CABG was associated with a lower 4-year rate of cardiovascular death or myocardial infarction compared to conservative management, but the impact on all-cause mortality was uncertain.
ISCHEMIA 3-vessel disease

Editorial

Oct 31
The CABG phoenix
John A. Bittl
The U.S. coronary revascularization guidelines downgraded the recommendation for using CABG surgery to improve survival in patients with multivessel chronic coronary disease, but future studies may provide evidence for a survival advantage of CABG.
free

Original Research

Oct 31
Accuracy of CT-μFR
Tingwen Weng, Shengxian Tu, et al.
The CAREER Study found that the patient-level accuracy of coronary computed tomography angiography (CCTA)-derived Murray law-based quantitative flow ratio (CT-μFR) was 89.6%, with high sensitivity and specificity, in identifying patients with hemodynamically significant coronary stenosis.
Accuracy of CT-μFR

Oct 25
TCT Conference 2024

The EuroIntervention team and Editors will be present at TCT 2024 in Washington from October 27-30. Don’t miss the latest updates from the journal during the event.

TCT Conference 2024

Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved